Sanofi (SAN.PA)

93.35

+0.11

+(0.12%)

At close: April 24 at 5:35:13 PM GMT+2

Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed

Roche beat first-quarter sales expectations Thursday, while Sanofi's sales report came in mixed. Shares were muted in premarket trades.

Investor's Business Daily 5 hours ago

SNY

SNYNF
Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail

Sanofi is also investigating balinatunfib in rheumatoid arthritis, Crohn's disease and ulcerative colitis.

Clinical Trials Arena 9 hours ago

SNY
French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), up 20.1% year over year and 18.7% in constant currency. The company reported first-quarter sales of 9.89 billion euros ($10.42 billion), beating the consensus of $9.77 billion. This was driven by launches, Dupixent, and favorable Beyfortus phasing. Sales increased 10.8% year over year and 9.7% on constant currency. U.S. sales were 4.66 billion and increased by 15.4%. The

Benzinga 12 hours ago

SNY

IPH.PA
Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth

SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025.

Zacks 14 hours ago

SNY

PFE
Sanofi stays on course amid tariff turmoil

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical tariffs given their “speculative” nature, its CFO told analysts.

BioPharma Dive 15 hours ago

SNY
Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug

The pharmaceutical company said the profit was driven by a higher gross margin and slower operating expense growth.

The Wall Street Journal 17 hours ago

SNY

SNYNF
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed

Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER1 and business EPS2 of €1.79 Pharma launches reached sales of €0.8 billion, up 43.8%, driven by ALTUVIIIODupixent sales were €3.5 billion, up 20.3%Vaccines sales were €1.3 billion, up 11.4%, driven by favorable Beyfortus phasingResearch and Development expenses reached €1.8 billion, up 6.9%Selling, general and administrative expenses were €2.2 billion, up 3.8%Business EPS was €1.79, up 1

GlobeNewswire 20 hours ago

SNY

SNYNF
Why vaccine makers aren't worried about Trump administration cuts

Vaccines have been a central focus for Trump's health leaders, but large-cap players aren't feeling the sting.

Yahoo Finance yesterday

MRNA

MRK

SNY
Update: Novartis, Sanofi CEOs Say EU Should Hike Drug Prices to Boost Innovation

(Updates with response from European Commission in the last three paragraphs.) Novartis (NVS) Chi

PREMIUM
MT Newswires yesterday

NVS

SNY
European Equities Surge Higher in Wednesday Trading; EC Fines Meta, Apple for DMA Violations

The European stock markets closed sharply higher in Wednesday trading as the Stoxx Europe 600 climbe

PREMIUM
MT Newswires yesterday

BCS

SNY

META
Novartis, Sanofi CEOs Say EU Should Hike Drug Prices to Boost Innovation

Novartis (NVS) Chief Executive Vas Narasimhan and Paul Hudson, his counterpart at Sanofi (SNY) said

PREMIUM
MT Newswires yesterday

NVS

SNY
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi

Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi are part of the Zacks top Analyst Blog.

Zacks yesterday

ABBV

SNY

CELG-RT
Sanofi to Invest $17.2 Million in Innate Pharma as Part of Review of 2016 License Agreement

Innate Pharma SA (IPHA) and Sanofi (SNY) have agreed that the latter will invest up to 15 million eu

PREMIUM
MT Newswires yesterday

IPH.PA

SNY
European pharma companies push for higher drug prices in EU amid U.S. tariff threats

(Reuters) -European drugmakers are urging the EU to allow higher medicine prices, warning that without stronger investment incentives, the bloc would fall further behind the U.S., where tariff threats have triggered a wave of pharma investment announcements. AstraZeneca Chief Executive Officer Pascal Soriot said that just like Europe has stepped up its defense spending, it now must do the same and invest more to protect its health sovereignty amid a shifting world order. "Europe spends a substantially lower share of GDP on innovative medicines than the U.S. and, as a result, is falling behind in attracting R&D and manufacturing investments, putting its ability to protect the health of its own people at risk," Soriot said in a statement.

Reuters yesterday

NVS

SNY

JNJ
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?

Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.

Zacks 2 days ago

ABBV

CELG-RT

SNY
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria

The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.

Zacks 3 days ago

SNY

REGN
Sanofi and Regeneron’s dupilumab approved by FDA for urticaria

The decision is supported by data from the Phase III Study A and Study C clinical trials.

Pharmaceutical Technology 3 days ago

SNY

REGN
Regeneron, Sanofi announce FDA approval of Dupixent for CSU

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria who remain symptomatic despite histamine-1 antihistamine treatment. “Dupixent is the first new targeted treatment for chronic spontaneous urticaria, or CSU, in over ten years, with pivotal trials demonstrating its ability to help patients significantly reduce the hallmark

TipRanks 5 days ago

SNY

SNYNF

REGN
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment CSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approved TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced

GlobeNewswire 6 days ago

SNY

SNYNF

REGN
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placeboIn the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatmentCSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approved Paris and Tarrytown, NY,

GlobeNewswire 6 days ago

SNY

SNYNF

Performance Overview

Return	SAN.PA	CAC 40 (^FCHI)
YTD	-0.42%	+1.65%
1-Year	+10.86%	-7.28%
3-Year	+3.47%	+14.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Survey

Sanofi (SAN.PA)

Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed

Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail

French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth

Sanofi stays on course amid tariff turmoil

Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug

Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed

Why vaccine makers aren't worried about Trump administration cuts

Update: Novartis, Sanofi CEOs Say EU Should Hike Drug Prices to Boost Innovation

European Equities Surge Higher in Wednesday Trading; EC Fines Meta, Apple for DMA Violations

Novartis, Sanofi CEOs Say EU Should Hike Drug Prices to Boost Innovation

The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi

Sanofi to Invest $17.2 Million in Innate Pharma as Part of Review of 2016 License Agreement

European pharma companies push for higher drug prices in EU amid U.S. tariff threats

Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?

Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria

Sanofi and Regeneron’s dupilumab approved by FDA for urticaria

Regeneron, Sanofi announce FDA approval of Dupixent for CSU

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Performance Overview